Why the study?
Hypertension is the leading global risk factor for disability and death, primarily via cerebrovascular accidents and ischemic heart disease, necessitating an update on timely topics and recent advances.
This review provides an update on ten timely topics in hypertension management, including RAAS inhibitors in COVID-19, resistant hypertension, and primary aldosteronism.
Answers are grounded in this paper and cite their sources.
Offers clinicians a timely synthesis of hypertension topics; extends prior reviews but leaves open the need for prospective validation.
Hypertension is the leading risk factor for disability and death globally. This is attributed to two major complications of hypertension, cerebrovascular accidents (CVA) and ischemic heart disease. This update provides a concise overview of several timely hypertension topics. These topics were chosen based on recent significant advances in the field. Examples include the use of renin-angiotensin-aldosterone inhibitors in coronavirus disease 2019 (COVID-19) patients, the landmark Systolic Blood Pressure Intervention Trial (SPRINT), management of resistant hypertension, and primary aldosteronism. The articles reviewed also include other recent landmark clinical trials, prior clinical trials of great significance, and medical societies guidelines. Ten topics were chosen based on their relevance to the practicing clinician. Each topic is discussed in a condensed manner highlighting recent advances in the field of hypertension.
No takes yet. Share an insight, caveat, or question.
Mohammad Tinawi (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: